Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study

被引:35
作者
Causse, X
Payen, JL
Izopet, J
Babany, G
Girardin, MFS
机构
[1] Toulouse Univ Hosp, Toulouse, France
[2] Lyon Univ Hosp, Lyon, France
[3] Nice Univ Hosp, Nice, France
[4] Pau Gen Hosp, Pau, France
[5] Villeneuve St Georges Gen Hosp, Villeneuve St Georges, France
[6] Broussais Univ Hosp, Paris, France
[7] Bordeaux Pessac Univ Hosp, Bordeaux, France
[8] Tours Univ Hosp, Tours, France
[9] Creteil Univ Hosp, Creteil, France
[10] Metz Reg Hosp, Metz, France
[11] Besancon Univ Hosp, Besancon, France
[12] Grenoble Univ Hosp, Grenoble, France
[13] Rothschild Univ Hosp, Paris, France
[14] Cochin Univ Hosp, Paris, France
[15] Rennes Univ Hosp, Rennes, France
[16] Beaujon Univ Hosp, Paris, France
[17] Strasbourg Univ Hosp, Strasbourg, France
[18] Compiegne Gen Hosp, Amiens, France
[19] Marseille Univ Hosp, Marseille, France
[20] CBMS, Paris, France
[21] ACTGene Evry, Evry, France
[22] Orleans Reg Hosp, Orleans, France
关键词
chronic hepatitis C; hepatitis C virus; HIV infection; human immunodeficiency virus; interferon treatment;
D O I
10.1016/S0168-8278(00)80105-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aim: The aim of this prospective study was to compare the response to alfa-interferon treatment of chronic hepatitis C in two groups of patients: coinfected with human immunodeficiency virus (HIV) (G I) or not (G II). Methods: One hundred and fifty-three patients with chronic hepatitis C had been enrolled in 30 French liver units or infectious diseases units between May 1992 and January 1995 (G I: 76, G II: 77) to receive alfa-2a interferon: 3 MU thrice weekly for 6 months. Results: One hundred and twenty-seven patients (G I: 63, G II: 64) fulfilled all criteria for analysis. The two groups were comparable for all demographic data, while significantly more severe biological and histological (p=0.001) parameters attested to more serious hepatitis among HIV-HCV coinfected patients. HCV viremia was higher among HIV-coinfected patients (p=0.0169), while genotype repartition was identical among the two groups (more than 52% of genotype 1, more than 31% of genotype 3). ALT normalization was, respectively, (G I/G II) obtained in 17.46%/26.56% (not significant) of patients at the end of treatment and in 11.11%/12.5% (not significant) of patients after 6 months of follow-up. In a multivariate analysis, GGT level before therapy (relative risk 2.1, confidence interval 1.1-5.8) and body surface area (relative risk 1.9, confidence interval 1.1-3.7) were the variables independently associated with the response to alfa-interferon treatment (higher GGT and more elevated body surface area were associated With a risk of non-response). Conclusion: In our study HIV infection did not affect the alfa-interferon treatment response of chronic hepatitis C, and response could be achieved among HIV-coinfected patients. Present therapeutic anti-HCV schedules need to be proposed to HIV-HCV coinfected patients before severe immunosuppression occurs. On the other hand, more severe biological and histological parameters were observed among HIV-HCV coinfected patients, which suggests a need to study whether HIV infection is associated with a worsening course of chronic hepatitis C.
引用
收藏
页码:1003 / 1010
页数:8
相关论文
共 49 条
  • [41] Hepatitis C in human immunodeficiency virus-coinfected patients: Increased variability in the hypervariable envelope coding domain
    Sherman, KE
    Andreatta, C
    OBrien, J
    Gutierrez, A
    Harris, R
    [J]. HEPATOLOGY, 1996, 23 (04) : 688 - 694
  • [42] QUANTITATIVE-EVALUATION OF HEPATITIS-C VIRUS-RNA IN PATIENTS WITH CONCURRENT HUMAN-IMMUNODEFICIENCY-VIRUS INFECTIONS
    SHERMAN, KE
    OBRIEN, J
    GUTIERREZ, AG
    HARRISON, S
    URDEA, M
    NEUWALD, P
    WILBER, J
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (10) : 2679 - 2682
  • [43] Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus
    Soriano, V
    GarciaSamaniego, J
    Bravo, R
    Gonzalez, J
    Castro, A
    Castilla, J
    MartinezOdriozola, P
    Colmenero, M
    Carballo, E
    Suarez, D
    RodriguezPinero, FJ
    Moreno, A
    delRomero, J
    Pedreira, J
    GonzalezLahoz, J
    LopezCalvo, S
    Llibre, JM
    Santamaria, JM
    GonzalezAnglada, I
    MartinezZapico, R
    Vazquez, JJ
    MartinezVazquez, JM
    Rodriguez, C
    Garcia, S
    Martin, R
    Bru, F
    Vicario, JL
    Arroyo, E
    Cosin, J
    Zabay, JM
    Mas, A
    Munoz, F
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) : 585 - 591
  • [44] HIGH-RATE OF COINFECTION WITH DIFFERENT HEPATITIS-C VIRUS SUBTYPES IN HIV-INFECTED INTRAVENOUS DRUG-ADDICTS IN SPAIN
    SORIANO, V
    NEDJAR, S
    GARCIASAMANIEGO, J
    BRAVO, R
    CASTRO, A
    GONZALEZ, J
    MARTINEZODRIOZOLA, P
    PEDREIRA, J
    DELROMERO, J
    SUAREZ, D
    LLIBRE, JM
    GONZALEZLAHOZ, J
    [J]. JOURNAL OF HEPATOLOGY, 1995, 22 (05): : 598 - 599
  • [45] Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
    Soto, B
    SanchezQuijano, A
    Rodrigo, L
    delOlmo, JA
    GarciaBengoechea, M
    HernandezQuero, J
    Rey, C
    Abad, MA
    Rodriguez, M
    Gilabert, MS
    Gonzalez, F
    Miron, P
    Caruz, A
    Relimpio, F
    Torronteras, R
    Leal, M
    Lissen, E
    [J]. JOURNAL OF HEPATOLOGY, 1997, 26 (01) : 1 - 5
  • [46] THE PROGRESSION OF HCV-ASSOCIATED LIVER-DISEASE IN A COHORT OF HEMOPHILIC PATIENTS
    TELFER, P
    SABIN, C
    DEVEREUX, H
    SCOTT, F
    DUSHEIKO, G
    LEE, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (03) : 555 - 561
  • [47] Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users
    Thomas, DL
    Shih, JW
    Alter, HJ
    Vlahov, D
    Cohn, S
    Hoover, DR
    Cheung, L
    Nelson, KE
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (04) : 690 - 695
  • [48] TSUBOTA A, 1994, HEPATOLOGY, V19, P1088, DOI 10.1016/0270-9139(94)90854-0
  • [49] YAMADA G, 1995, HEPATOLOGY, V22, P1351, DOI 10.1016/0270-9139(95)90135-3